Erectile dysfunction (ED) is undoubtedly common. In 1992 a National Institutes of Health Consensus Panel 1 defined it as the persistent inability to achieve or maintain an erection satisfactory for sexual function. A generally accepted estimate is that 10% of all men have some sort of problem, with a prevalence of 39% in men 40 years old to 67% among those 70 years old and varying from intermittent and partial difficulty to total inability to obtain an erection. 2 This means that there will be some 2-3 million men in the UK suffering from erectile problems. Twenty years ago it was widely thought that ED was psychological in origin, but now it is recognised that causes can be organic or psychological, or a mixture of both.
Since oral treatment with sildenafil citrate (Viagra) became available in 1998, it has become licensed in 50 countries. A lot of experience has been obtained on its uses and its contraindications. Undoubtedly, it has been very successful, but widespread general experience in the UK has been limited because the Department of Health has only recently decided on its partial availability on the NHS apart from certain categories listed in Schedule 11.
Penile erection is a haemodynamic event. 3 With either central or local sexual stimulus, arterial endothelial cells and cavernosal nerve endings in the penis release nitric oxide (NO). This stimulates the formation of cyclic guanothene-monophosphate (cGMP), and this in turn leads to the relaxation of corpus cavernosal smooth muscle, allowing vascular filling and consequent erection. Detumescence is obtained and maintained by degradation of cGMP by type 5 phosphodiesterase (PDE5) as well as the action of the sympathetic. Sildenafil is a highly selective inhibitor of PDE5 and by preventing the breakdown of cGMP, it prolongs its action and opposition to penile erection is reduced, enabling it to be initiated or maintained. on basal vascular tone. Studies from two London teaching hospitals 5 to assess the effects of sildenafil on blood pressure, heart rate and cardiac output, show that in eight healthy volunteers there were significant falls in supine systolic and diastolic blood pressures with a mean maximum decrease of systolic/diastolic pressure of 10/7 mm Hg, but there was no evidence of an orthostatic effect. Blood pressure returned to baseline values 6 h after dosing. There were no effects on the subjects' heart rate or cardiac index. Eight subjects with stable ischaemic heart disease showed only small reductions in right atrial pressure, pulmonary arterial occluded pressure and systolic and diastolic pressures at rest, with heart rate relatively unchanged. It can therefore be seen that sildenafil has modest vasodilating properties.
Therapeutic organic nitrates also release NO, enhancing the production of cGMP leading to vasodilatation and consequently a small fall in systemic blood pressure. A Scottish study 6 looked at the effects of sildenafil coadministered with glyceryl trinitrate in 12 healthy males and showed that it can potentiate the hypotensive effects of nitrates to such an extent that the fall in systolic blood pressure was Ͼ25 mm Hg and may have been greater if the subjects (11 out of 12) had not removed the sublingual tablet in less than 5 min. The subjects were significantly less tolerant of intravenous glyceryl trinitrate. As a result, the authors concluded that this synergistic effect of glyceryl trinitrate is likely to occur with all organic nitrates and NO donors. Because of the risk of clinically significant hypotension, subjects on nitrate therapy were excluded from later stages of clinical trials of sildenafil, and the product labelling stated that its use is strictly contraindicated in patients with ED who are using nitrates in any form, including recreational nitrates such as 'poppers'. Interestingly, however, it is not yet known after what interval nitrates could be given to someone who has taken a dose of sildenafil.
Another phase one trial was carried out on 16 hypertensive patients who were on a calcium antagonist (amlodipine) and no significant differences were seen in blood pressure and heart rate. 6 It was concluded that there was no synergistic reaction between amlodipine and sildenafil, only additive as might have been expected, as amlodipine does not work by involving the cGMP pathway of vascular smooth muscle. As other antihypertensives other than nitrates or NO donors also do not work through the cGMP pathway, it was assumed that there is unlikely to be a synergistic action with them.
Other side effects seen in a total of 3700 patients 7 were headache (16%), flushing (10%), and dyspepsia (7%), nasal congestion (3%), and blue tinged vision (0.1%), all of which were mild and transient, but which increased with increasing doses up to the largest recommended dose of 100 mg.
Where does that leave us with using sildenafil? How effective is the drug going to be in daily practice on many different types of men? As erectile dysfunction is so common and increases in incidence with age, one would naturally expect concomitant morbidities which are either under treatment or are still undiagnosed, or alternatively cardiologists may be managing patients who are already being treated for impotence. The questions arise as to whether giving sildenafil to a cardiovascularly compromised patient should be discouraged and if so, what are the criteria? The American College of Cardiology and the American Heart Association recommend 8 that although the known cardiovascular effects of sildenafil were relatively minor, heart disease patients represented only a small fraction of those studied, and as patients with heart failure, myocardial infarction or stroke within 6 months as well as patients with uncontrolled hypertension were not included in the original trials, there yet may be unforeseen problems in this group.
Their clinical recommendations conclude that giving nitrates and sildenafil concurrently is completely contraindicated and that it may be potentially hazardous to give sildenafil to patients who have active coronary ischaemia but who are not on nitrates, those who have congestive cardiac failure and borderline low blood pressure, those on complicated antihypertensive drug regimens and those on drugs that can prolong the half-life of sildenafil, such as some antibiotics (erythromycin, ketaconazole), some CNS drugs (fluoxetine, fluvoxamine, carbamazepine, phenytoin), the statins and others such as cimetidine, omeprazole and astemizole. Because sildenafil reacts occasionally with the PDE6 found in the retina and causes a temporary blue tinge to vision, it is also contraindicated in retinitis pigmentosa. These recommendations will undoubtedly be modified as experience of use of the drug grows.
A large number of patients with erectile dysfunction with a wide range of aetiologies have been treated with sildenafil. Knowing what other drugs, including over the counter drugs, that the patient has been taking is crucial as a wide range affect erectile function. 9 Gradually the reports are coming in but need to be scrutinised carefully. For example, a randomised controlled trial of diabetics 10 reports that 56% of diabetic patients with ED put on sildenafil reported 'improved erections' according to the International Index of Erectile Function. 11 But what is 'improved'? The state of satisfaction is a very subjective one. In fact, only 48% were able to achieve penetrative intercourse on one occasion. The list of iatrogenic causes of ED seems to grow unwittingly larger. Certainly, we have a duty to warn a man that certain treatments for other conditions could make him impotent. Do we try the treatment and see its effect, realising that it may be difficult for him to regain normal potency if it is discontinued, do we modify it in anticipation although it may not be the optimum treatment, or do we wait and give sildenafil when he does get a problem? Above all, will there actually be a different safety profile in a few years time?
There are many unanswered questions which will only become clear in time as the drug is more widely used.
